Sodium–glucose cotransporter 2 inhibitors (SGLT2i) may induce an early post-initiation decrease of estimated glomerular filtration rate (eGFR), which does not impact the SGLT2i benefits. The occurrence, characteristics, determinants, and clinical significance of an initial eGFR change among patients with heart failure with reduced ejection fraction require further study. In this study we aimed to describe eGFR change from randomization to week 4 (as percent of change relative to randomization) and assess its impact in EMPEROR-Reduced.

中文翻译：

---

EMPEROR-Reduced 中开始使用恩格列净后估计肾小球滤过率的早期变化

钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 可能会导致估计肾小球滤过率 (eGFR) 在启动后早期下降，但这不会影响 SGLT2i 的益处。射血分数降低的心力衰竭患者初始 eGFR 变化的发生、特征、决定因素和临床意义需要进一步研究。在本研究中，我们旨在描述从随机化到第 4 周的 eGFR 变化（相对于随机化的变化百分比）并评估其对 EMPEROR-Reduced 的影响。